Works matching IS 14783223 AND DT 2024 AND VI 44 AND IP 5


Results: 19
    1
    2

    Issue Information.

    Published in:
    Liver International, 2024, v. 44, n. 5, p. 1071, doi. 10.1111/liv.15940
    Publication type:
    Article
    3
    4

    Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab.

    Published in:
    Liver International, 2024, v. 44, n. 5, p. 1108, doi. 10.1111/liv.15885
    By:
    • Rimini, Margherita;
    • Stefanini, Bernardo;
    • Tada, Toshifumi;
    • Suda, Goki;
    • Shimose, Shigeo;
    • Kudo, Masatoshi;
    • Finkelmeier, Fabian;
    • Yoo, Changhoon;
    • Presa, José;
    • Amadeo, Elisabeth;
    • genovesi, Virginia;
    • De Grandis, Maria Caterina;
    • Iavarone, Massimo;
    • Marra, Fabio;
    • Foschi, Francesco;
    • Tamburini, Emiliano;
    • Rossari, Federico;
    • Vitiello, Francesco;
    • Bartalini, Linda;
    • Soldà, Caterina
    Publication type:
    Article
    5
    6
    7

    Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort.

    Published in:
    Liver International, 2024, v. 44, n. 5, p. 1129, doi. 10.1111/liv.15878
    By:
    • Tang, Liang‐Jie;
    • Sun, Dan‐Qin;
    • Song, Sherlot Juan;
    • Yip, Terry Cheuk‐Fung;
    • Wong, Grace Lai‐Hung;
    • Zhu, Pei‐Wu;
    • Chen, Sui‐Dan;
    • Karsdal, Morten;
    • Leeming, Diana Julie;
    • Jiang, Pei;
    • Wang, Cong;
    • Chen, Qiang;
    • Byrne, Christopher D.;
    • Targher, Giovanni;
    • Eslam, Mohammed;
    • George, Jacob;
    • Wong, Vincent Wai‐Sun;
    • Zheng, Ming‐Hua
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19